Success Metrics

Clinical Success Rate
90.7%

Based on 49 completed trials

Completion Rate
91%(49/54)
Active Trials
9(10%)
Results Posted
8%(4 trials)
Terminated
5(6%)

Phase Distribution

Ph early_phase_1
3
3%
Ph not_applicable
24
28%
Ph phase_1
14
16%
Ph phase_2
17
20%
Ph phase_3
16
18%
Ph phase_4
8
9%

Phase Distribution

17

Early Stage

17

Mid Stage

24

Late Stage

Phase Distribution82 total trials
Early Phase 1First-in-human
3(3.7%)
Phase 1Safety & dosage
14(17.1%)
Phase 2Efficacy & side effects
17(20.7%)
Phase 3Large-scale testing
16(19.5%)
Phase 4Post-market surveillance
8(9.8%)
N/ANon-phased studies
24(29.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.3%

49 of 61 finished

Non-Completion Rate

19.7%

12 ended early

Currently Active

9

trials recruiting

Total Trials

87

all time

Status Distribution
Active(12)
Completed(49)
Terminated(12)
Other(14)

Detailed Status

Completed49
unknown14
Withdrawn7
Active, not recruiting5
Terminated5
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
87
Active
9
Success Rate
90.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (3.7%)
Phase 114 (17.1%)
Phase 217 (20.7%)
Phase 316 (19.5%)
Phase 48 (9.8%)
N/A24 (29.3%)

Trials by Status

recruiting45%
active_not_recruiting56%
terminated56%
withdrawn78%
completed4956%
unknown1416%
not_yet_recruiting33%

Recent Activity

Clinical Trials (87)

Showing 20 of 87 trialsScroll for more
NCT07569861Not Applicable

Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome

Not Yet Recruiting
NCT03851159Not Applicable

Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota

Active Not Recruiting
NCT07433023Phase 2

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

Not Yet Recruiting
NCT06540352Phase 2

A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form

Active Not Recruiting
NCT05325502Not Applicable

Does Caffeine Facilitate Human Reward Learning Behaviors?

Active Not Recruiting
NCT06473779Phase 3

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Active Not Recruiting
NCT05660850Phase 2

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Completed
NCT04428372Phase 2

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Completed
NCT06884657Phase 4

Effect of Mannitol on Propofol Level

Recruiting
NCT07080567Phase 2

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Recruiting
NCT06914310Phase 2

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Not Yet Recruiting
NCT06846307Phase 3

The Effect of Mannitol Volume with Changes in Osmolarity in Traumatic Brain Injury

Completed
NCT06841406Phase 4

Budesonide as a Treatment for Functional Dyspepsia

Recruiting
NCT04385264Phase 2

#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19

Withdrawn
NCT06105671Not Applicable

U-LABA/ICS Effects on Exercise Performance, Formoterol

Completed
NCT06400355Not Applicable

Effect of Mannitol on Recovery Pattern After Orthognathic Surgery

Active Not Recruiting
NCT04217421Phase 3

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

Recruiting
NCT05305508Phase 2

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

Completed
NCT04135456Phase 1

The Optimal Dose of Mannitol for Intraoperative Brain Relaxation During the Operation of Aneurysmal Subarachnoid Hemorrhage

Unknown
NCT03162653Phase 3

Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome

Unknown

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
87